TIGARD, Ore., April 22, 2014 /PRNewswire/ -- Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer of needle-free injection systems announced the appointment of Needle Free Solutions, LLC as the company's exclusive distributor for Pain Management applications in North America. The agreement calls for the sale of the Biojector®2000 gas-powered device and accessories for use in the application.
"We are excited to be the exclusive distributor of the Bioject's B2000 Needle-Free Injection System for use with pain management applications in both clinics and hospitals," said Dr. Michael Duzey, President of Needle Free Solutions. "We have found that both clinicians and patients have been pleased with the needle-free injections system. Clinicians are excited and satisfied with the ease of use of the injection and patients prefer needle-free to the traditional needle and syringe delivery."
"Needle Free Solutions, Dr. Duzey and his group bring special expertise and capabilities to this important area," according to Mark Logomasini, Bioject's President and CEO. "With Bioject's proven technology and Needle Free Solutions understanding of patient needs, this collaboration will significantly increase the options available for treatment."
Bioject also announced the appointment of iHealthNet, LLC as the company's representative in the European Union. "The partnership with iHealthNet in South Asia, the Middle East, and Africa has been very successful," stated Mark Logomasini, Bioject's President and CEO. "When it came to increasing our presence in Europe, it was an easy decision to expand our relationship with iHealthNet."
Tawfiq Hassan, CEO of iHealthNet commented, "Responding to the increasing cost of healthcare services and keeping safety and ease of use in mind, Bioject's needle-free injection therapy devices are the best option iHealthNet can offer to the European and African markets immediately," and also added "We are very excited to be able to bring the latest in needle-free syringe devices within their reach."
Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations.
Needle Free Solutions is located in Mundelein, Illinois, USA and dedicated to providing safe and advanced therapies for pain management healthcare providers and patients.
iHealthNet, LLC. is a US registered company comprised of a talented group of biotechnology enthusiasts with the common goal of providing advanced and cost-effective healthcare solutions to patients and medical practitioners on an individual, collective, and nationwide basis.
Readers and potential investors are cautioned that an investment in the Bioject's securities involve an EXTREMELY high degree of risk. Such risks include, without limitation, the risk that the distribution agreement will not be successful due to the time required in obtaining government clearances and the risk that the Company may be unable to comply with the extensive government regulations applicable to the international business. Bioject (OTC Pink: BJCT) trades on the OTC Pink tier of the OTC market. Investors can find Real-Time quotes and market information for the Company on www.otcmarkets.com.
SOURCE Bioject Medical Technologies Inc.